XML 145 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1

Accounts payable and accrued expenses

12 Months Ended

Dec. 31, 2024

Payables and Accruals [Abstract]

Accounts payable and accrued expenses

6. Accounts payable and accrued expenses

Accounts payable and accrued expenses at December 31, 2024 and 2023 consist of the following:

​

​	​	​	​	​	​	​
​	​	December 31,
​	​	2024			2023
Employee compensation, benefits, and related accruals	​	$	61,575	​	$	62,643
Income tax payable	​	​	4,701	​	​	—
Consulting and contracted research	​		19,909	​		27,500
Sales allowance	​		58,644	​		77,176
Sales rebates	​		101,613	​		131,334
Royalties	​	​	8,953	​	​	74,111
Accounts payable	​		17,274	​		6,045
Milestone payable	​	​	11,025	​	​	2,500
Other	​		20,598	​		10,674
Total	​	$	304,292	​	$	391,983

​

As of December 31, 2024 and December 31, 2023, there were $0.1 million and $9.0 million, respectively, of accrued restructuring costs included above within employee compensation, benefits, and related accruals from a reduction in

workforce in the year ended December 31, 2023 in connection with the Company’s strategic pipeline prioritization and discontinuation of its preclinical and early research programs in its gene therapy platform.

X

- Definition

The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483384/720-30-45-1

+ Details

Name:	us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration